Myanmar
Search
Sign In
Rheumatology
Top Medical News
Women who consume anthocyanin-rich foods in high amounts appear to have a lower prevalence of hyperuricaemia, regardless of the presence of metabolic syndrome, as reported in a study.
In people with rheumatic and musculoskeletal diseases (RMDs), inactivated COVID-19 vaccines prove safe and effective at lowering the risk of COVID-19–related pneumonia, as shown in a study from China.
Left ventricular (LV) diastolic dysfunction (LVDD) in systemic sclerosis (SSc)-associated interstitial lung disease (ILD) shows a greater association with traditional LVDD than SSC-specific risk factors, reveals a study. Of note, SSc-ILD patients with LVDD appear to have worse dyspnoea and survival.
Use of biologic disease-modifying antirheumatic drugs (bDMARDs), particularly tocilizumab (TCZ), anakinra (ANK), and canakinumab (CNK), appears safe and effective in the treatment of adult-onset Still disease (AOSD), results of a systematic review and meta-analysis have shown.
Patients differ from physicians regarding their views of systemic lupus erythematosus (SLE) flares, a study has found. The former see flares as days of having fatigue, pain, and skin issues, while the latter define flares as periods of elevated clinical SLE activity.
Weight-bearing recreational physical activities may lead to knee osteoarthritis (OA) in individuals with low levels of lower-limb muscle mass, according to a study.
Children and adolescents with overweight and obesity may be predisposed to low back pain, according to a systematic review and meta-analysis.
Conference Reports
Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).
Half of gout patients receiving novel uricase analogue infusions, along with a proprietary rapamycin formulation, got their serum urate controlled in two phase III studies presented at EULAR 2023.
Patients initiated on gliflozins or flozins – also called sodium-glucose co-transporter 2 (SGLT2) inhibitors – for type 2 diabetes (T2D) who were previously on metformin had reductions in the incidents of gout of up to 60 percent compared with other second-line agents in a recent study.
In the phase III STRIDES X-Ray Extension study, additional doses of the investigational CLK/DYRK inhibitor lorecivivint delivered favourable outcomes for individuals with advanced knee osteoarthritis (OA).
Treatment with dazodalibep, a novel nonantibody fusion protein that acts as an antagonist of CD40 ligand, significantly reduced symptom burden in adults with Sjögren’s syndrome, according to the ALISS trial presented at EULAR 2023.
In the treatment of chronic glucocorticoid users with high fracture risk, romosozumab yields higher gains in spine bone mineral density (BMD) compared with denosumab, as shown in a pilot trial presented at EULAR 2023.
It is now possible to predict rheumatoid arthritis (RA), thanks to interpretations of magnetic resonance imaging (MRI) scans made by an artificial intelligence (AI) model.